What are the three types of HIV tests available to patients, how do they differ, and how can patients determine the best ...
HIV exhausts the body's immune system by overactivating it, despite effective antiviral treatment. Researchers from Linköping University in Sweden have conducted cell studies showing that an existing ...
Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.
The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
The HIV prevention shot lenacapavir will be rolled out at South African clinics within the next few months – from 2027, the ...
A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according ...
The HIV prevention shot lenacapavir will be rolled out at South African clinics within the next couple of months — from 2027, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results